Full-Time

Manager, Benefits Operations

Updated on 8/9/2026

Deadline 12/31/26
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Global biopharma researching, developing, delivering medicines

Compensation Overview

PLN150k - PLN181.8k/yr

+ Incentive cash + Stock opportunities

Dublin, Ireland

Hybrid

50% hybrid work schedule; occasional travel may be required.

Bachelor's

Category
People & HR (1)
Required Skills
Microsoft Office
ServiceNow
Workday HRIS
Mergers & Acquisitions (M&A)
Excel/Numbers/Sheets

Get referred to Bristol Myers Squibb

See people who can refer or advise you

Requirements
  • A bachelor's degree in Human Resources, Business Administration or a related field, or equivalent experience.
  • A minimum of 5 years of hands-on experience in benefits administration.
  • Experience with self-insured benefit plans or large, complex benefits programs.
  • Experience with benefits administration software and human resources information systems platforms.
  • Knowledge of human resources policies, processes, and regional benefits-related legislation.
  • Experience working in fast-paced, complex environments while managing multiple priorities.
  • Strong analytical skills and proficiency in Excel, including VLOOKUPs and pivot tables, and Microsoft Office.
  • Ability to interpret and present complex benefits data.
  • Ability to explain complex benefits information clearly to stakeholders at all levels.
  • Ability to collaborate across a global, multifunctional organization and deliver individual goals with minimal supervision.
  • Ability to work in a typical office environment.
  • Ability to work a 50% hybrid schedule.
Responsibilities
  • Oversee end-to-end operations of benefits programmes, including medical, pensions, dental, vision, life insurance, disability, wellness programs and other ancillary plans, ensuring efficiency and a positive customer experience as the second level of expertise.
  • Serve as a senior subject matter expert and consultant for the team and People Services on benefits operations activities.
  • Partner with Benefit Strategists and product design to determine the feasibility of proposed benefit additions or modifications, and participate in implementation meetings by providing subject matter expertise for operationalization of plans and processes.
  • Implement operational changes and identify opportunities for process automation to reduce manual tasks and create streamlined, efficient processes.
  • Oversee and monitor eligibility, enrollments, status changes, terminations, claims, provider portal updates, and payment processes.
  • Manage renewals, enrollment windows, and annual activity calendars, including Annual Enrollment planning and execution, in partnership with internal and external stakeholders.
  • Analyze enrollment data to identify trends and opportunities for improvement.
  • Identify trends from employee feedback and experiences and determine solutions to meet business needs.
  • Monitor and analyze employee benefits utilization, costs, and trends to identify cost-saving, optimization, and program-improvement opportunities.
  • Interpret, communicate, and document benefit plan provisions and processes to continuously enhance workflows.
  • Review and update employee reference materials, Knowledge Articles, and work instructions in the internal database and benefits system.
  • Act as an escalation point for complex benefits issues, providing solutions and guidance.
  • Use ServiceNow to research and resolve Tier 2 benefits cases.
  • Create and set controls over benefit utilization and payments.
  • Prepare financial reports, create and manage purchase orders, and process, audit, and reconcile invoices for carriers and vendors.
  • Specify and implement system changes, conduct testing, and train team members.
  • Lead implementations, enhancements, testing, and deployment of BMS benefits plans and systems.
  • Coordinate mergers and acquisitions activities for Benefits Operations, including employee data-load coordination, enrollment windows, M&A concessions, Prism reports, and historical archiving requirements.
  • Collaborate with internal partners, carriers, and vendors to create and deliver training resources, webinars, workshops, and informational materials for benefits offerings.
  • Stay informed about industry best practices, emerging trends, and regulatory changes related to benefits operations.
Desired Qualifications
  • Professional certifications such as CIPD.
  • Knowledge of Medicare and retirement programs.
  • Familiarity with Workday and Benifex.
  • Prior experience implementing new benefits technologies, upgrading systems, and redesigning operations.
  • Project manager exposure.
  • Occasional travel may be required.

Bristol Myers Squibb develops and sells medicines for serious diseases, focusing on cancer, immune system disorders, and cardiovascular conditions. Its work starts with research and development to create new therapies, which are then approved by regulators before being used by doctors and patients; the company also offers generic versions and supports biosimilars to expand access. BMS differentiates itself with a broad portfolio of innovative medicines alongside affordable options and a strong emphasis on ESG and regulatory engagement. The goal is to improve patient health by delivering effective, affordable medicines and advancing sustainable healthcare globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Get referred to Bristol Myers Squibb

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 30, 2026 earnings beat estimates, with revenue $12.97 billion and EPS $2.04.
  • BMS raised 2026 revenue guidance to $49 billion-$50 billion and EPS to $6.75-$7.00.
  • Camzyos priority-review, mezigdomide NDA, and Hengrui licensing expand near-term catalysts.

What critics are saying

  • Eliquis and Opdivo face patent erosion by 2028, compressing BMS's largest cash engines.
  • AstraZeneca merger talks invite FTC scrutiny, divestitures, and distraction before 2027 decisions.
  • Late readouts for milvexian, COBENFY, and other pipeline assets expose execution failure.

What makes Bristol Myers Squibb unique

  • BMS combines oncology scale with immunology, cardiology, and cell-therapy franchises.
  • Camzyos, Reblozyl, Breyanzi, and Opdivo Qvantig diversify revenue beyond legacy drugs.
  • AI deals with NVIDIA, Anthropic, and Schrödinger deepen drug-discovery capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

7%

2 year growth

7%
Yahoo Finance
Aug 7th, 2026
BMS claims pharma's most powerful supercomputer with Nvidia, beating Lilly and Roche

Bristol Myers Squibb announced an expanded partnership with Nvidia to build what it claims will be "the most powerful and energy-efficient single-owned Nvidia infrastructure in life sciences". BMS joins Eli Lilly and Roche in staking supercomputer superlative claims, though companies use different metrics to measure power. According to Nvidia, BMS' planned system will be the most advanced by operations per second, whilst others measure by GPU count or single system capacity. The companies are pursuing greater computing power to train larger models, run more complex experiments, and accelerate drug discovery. BMS has worked with Nvidia for nearly three years. The company previously used AI to overcome a plateau whilst searching for a clinical candidate for a sickle cell programme. Under the expanded deal, BMS will deploy Nvidia's DGX SuperPOD supercomputer, delivering up to ten times greater performance per megawatt than its predecessor.

Yahoo Finance
Aug 5th, 2026
Bristol Myers Squibb deploys Schrödinger's AI co-scientist Bunsen for drug discovery

Schrödinger has announced a strategic collaboration with Bristol Myers Squibb to deploy Bunsen, its agentic AI co-scientist, within BMS's research organisation. The agreement expands upon their existing partnership, enabling BMS scientists to explore more scientific possibilities and accelerate discovery decisions. Under the collaboration, Schrödinger will work with BMS scientists to develop novel functionality within Bunsen alongside its computational technologies and RetroSynth AI-driven synthesis planning platform. Unlike general-purpose agents, Bunsen is optimised to execute Schrödinger's physics-based computational platform by planning and running complex molecular discovery workflows. The deployment allows BMS to scale its predict-first computational approach across a broader group of scientists, helping them navigate molecular design space more efficiently in discovering innovative medicines.

Yahoo Finance
Aug 3rd, 2026
AstraZeneca shares plunge 8%, wiping out $22B after Bristol Myers merger rumours

AstraZeneca and Bristol Myers Squibb have held initial discussions about a potential merger that would create a combined entity worth nearly $400 billion, according to reports citing people familiar with the matter. The market reaction was sharply negative, with AstraZeneca shares falling more than 8%, wiping out roughly $22 billion in market value, whilst Bristol Myers dropped almost 1.5%. The deal would strengthen AstraZeneca's cancer and cardiovascular drug portfolios, which accounted for 44% and 22% respectively of its $59 billion revenue last year. Bristol Myers faces upcoming patent losses for key drugs including immunotherapy Opdivo and blood thinner Eliquis. Analysts questioned the strategic rationale, noting AstraZeneca's recent success under CEO Pascal Soriot.

Merced Sun-Star
Aug 2nd, 2026
AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports.

AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports. By Reuters Reuters Updated August 2, 2026 4:05 PM Gift Article Aug 2 (Reuters) - UK drugmaker AstraZeneca has been exploring a deal to combine with U.S. rival Bristol Myers Squibb, the Financial Times reported on Sunday, citing people familiar with the matter. The deal could create one of the world's biggest pharmaceutical companies with a combined value of nearly $400 billion. The companies have held talks on a potential tie-up in recent months, the report said, adding that a deal could materialize soon, but could also be delayed or fall apart. Reuters could not immediately verify the report. AstraZeneca declined to comment, while Bristol Myers did not immediately respond to a Reuters request for comment. Last year, AstraZeneca unveiled plans for a direct U.S. listing, aiming to capitalize on stronger valuations in the U.S. market while remaining listed in London. STRONG GROWTH IN CANCER DRUGS AstraZeneca's share price has more than quadrupled during Pascal Soriot's 14-year tenure as CEO, soaring above the wider FTSE 100 index and main British rival GSK. Second-quarter results last week showed strong demand for cancer and rare disease drugs continues to drive growth. Cancer treatments accounted for about $25 billion in 2025 sales, nearly half of the total, followed by cardiovascular, renal and metabolism treatments worth about $12 billion. Combining with Bristol Myers, whose shares are up around 44% over the last year, could draw attention from antitrust regulators. Oncology drugs accounted for over 40% of its overall sales in the first six months of 2026, and the two companies' cancer immunotherapies directly compete. "I would expect a Trump FTC to scrutinize the merger and if there are significant overlaps in certain drugs and late stage pipeline overlaps it would require meaningful divestitures," said antitrust lawyer Andre Barlow with DBM Law Group, referring to the U.S. Federal Trade Commission. Bristol Myers has been doing smaller deals to gain new drugs as it faces declining sales of older medicines, some of which will soon face generic competition. In 2019, Bristol Myers bought Celgene for about $80 billion, acquiring its flagship blood cancer drug Revlimid, which became Bristol's top-selling product. Revlimid has already lost patent protection and its current top sellers - cancer immunotherapy Opdivo and blood thinner Eliquis - could lose patent protection by 2028. Barlow noted that in the deal for Celgene, the Trump FTC required Celgene to sell psoriasis treatment Otezla, a major divestiture at $13.4 billion. "There is bipartisan support to scrutinize pharma deals so I would imagine that even the Trump FTC would ask the broader questions relating to bundling of products and a lack of future innovation, in addition to scrutinizing all direct overlaps," he said. Bristol raised its full-year revenue and profit forecast last week as strong sales of Eliquis and newer medicines pushed second-quarter results well past analysts' estimates. Its promising newer drugs and pipeline assets include an experimental blood thinner milvexian, anemia treatment Reblozyl and heart drug Camzyos. The report of the potential deal comes about a dozen years after AstraZeneca fended off a takeover attempt by larger U.S. rival Pfizer. Large pharma deals have been rare in recent years, in part due to concerns about antitrust and U.S. pressure to keep drug prices low. Besides Bristol and Celgene, AbbVie bought Allergan in 2020 and Takeda and Shire combined in 2019. (Reporting by Devika Nair in Bengaluru and Michael Erman in New Jersey; Additional reporting by Chris Sanders in Washington; Editing by Caroline Humer and Bill Berkrot) This story was originally published August 2, 2026 at 12:36 PM.

Yahoo Finance
Jul 31st, 2026
Bristol Myers Squibb raises 2026 outlook as growth portfolio hits 60% of revenue

Bristol Myers Squibb reported second-quarter revenues of $12.97 billion, beating consensus estimates of $11.67 billion. Non-GAAP earnings per share came in at $2.04, surpassing the $1.59 estimate. The company's growth portfolio, which now represents nearly 60% of revenues, increased 15% to $7.56 billion. Chief executive Christopher Boerner highlighted strong performance from Reblozyl, Breyanzi, Camzyos, Opdualag and Opdivo Qvantig. Bristol Myers raised its full-year 2026 revenue guidance to approximately $49 billion to $50 billion from $46 billion to $47.5 billion. Non-GAAP earnings per share guidance increased to $6.75 to $7.00. The company also raised its Eliquis revenue growth outlook to 20% to 25% from a previous expectation of 10% to 15%.